Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose Escalation Trial to Evaluate Safety and Reactogenicity of Single IV Administration of P2G12

NCT02923999 is registered in ClinicalTrials.gov with St George's, University of London as lead sponsor.

NCT NCT02923999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02923999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose Escalation Trial to Evaluate Safety and Reactogenicity of Single IV Administration of P2G12
Lead sponsor
St George's, University of London
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2019
Completion date
December 31, 2020
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infection